EMBO recognizes 63 researchers for advances in life sciences
The European molecular biology Organization (EMBO) announced the recognition of outstanding research contributions by 63 life scientists from 14 countries. The researchers are awarded the life-long honour of EMBO membership, joining almost 1500 of the world’s leading molecular biologists.
“EMBO Members are the basis for the organization’s international reputation and our most valuable asset,” said Maria Leptin, EMBO Director. “We welcome this year’s group of exceptional scientists and look forward to their fresh input and ideas to advance the life sciences.”
Each year, the EMBO membership nominates and elects new members based on scientific excellence. Forty-nine from this year’s election work in countries across Europe and become EMBO Members. Fourteen of those elected work in the United States, Japan and Taiwan and are honoured as EMBO Associate Members. International mobility has been key for many of the new members and associate members as they progressed in their scientific careers, fostering innovative and collaborative research globally.
The 63 scientists represent a broad cross-section of research covering classical areas of molecular biology as well as rapidly developing fields such as systems biology, neuroscience and cancer biology. Many of them bridge across a number of fields, from biology to medicine, biochemistry or biophysics. Twelve female researchers are recognized this year.
By their involvement with the organization’s activities, the selected researchers will help shape the direction of the life sciences in Europe. More than half of the EMBO Members contribute by serving on advisory editorial boards of the organization’s four scientific journals, mentoring young researchers, providing expertise to EMBO programmes and taking the lead on new initiatives. Members also nominate candidates for the annual EMBO Gold Medal award.
Other news from the department people
Most read news
More news from our other portals
Last viewed contents
Sensitizing tumor response to cancer therapy
PANATecs GmbH Appoints Rainer Baule, Chairman of the Board of Fresenius Kabi AG, to the Advisory Board
Siegfried begins construction of new large-scale production plant in Minden (DE) - Total investment of up to CHF 100 million
Wyss Institute at Harvard University launches SPEAR Bio - Spear Bio is working towards commercializing its first assay, which accurately assesses levels of SARS-CoV-2-neutralizing antibodies in dried-blood spot samples
HIV infection: the brevity of the right moment
Study sheds light on treating cancer - Using light to target and kill cancer cells alternatively without surgery
First structural map of cystic fibrosis protein sheds light on how mutations cause disease
Scientists identify gene that predicts post-surgical survival from brain metastasis of breast cancer patients
Silver nanoparticles take spectroscopy to new dimension - A new way of organizing nanostructures has boosted Raman signals by a hundred thousand times to better identify and characterize different molecules
Software revolution for clinical trials - Health Tech Start-up Carelane Raises €800,000 in Pre-Seed Funding
Multitasking with perfection: Nerve cell works like 1400 individual cells - Amacrine cell in the fruit fly visual system consists of electrically isolated subunits
